Product Description
For Respiratory Syncytial Virus (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03333317)
Mechanisms of Action: Nucleoside Polymerase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Respiratory Syncytial Virus Infections|Pneumovirus Infections|Communicable Diseases|Respiratory Sounds
Phase 1: Respiratory Syncytial Virus Infections|Kidney Diseases|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03468777 |
CR108437 | P1 |
Terminated |
Healthy Volunteers |
2018-07-09 |
20% |
2019-03-22 |
Treatments |
JapicCTI-153040 |
JapicCTI-153040 | P1 |
Completed |
Respiratory Syncytial Virus Infections |
2018-05-31 |
|||
NCT03441529 |
CR108431 | P1 |
Completed |
Healthy Volunteers |
2018-05-03 |
20% |
2019-03-22 |
Treatments |
2013-005104-33 |
2013-005104-33 | P1 |
Completed |
Respiratory Syncytial Virus Infections |
2018-02-15 |
56% |
2025-06-08 |
Treatments |
NCT02202356 |
ALS-8176-503 | P1 |
Completed |
Respiratory Syncytial Virus Infections |
2018-02-15 |
56% |
2019-03-20 |
Treatments |
NCT03189498 |
CR108333 | P1 |
Completed |
Kidney Diseases |
2017-12-06 |
20% |
2019-03-21 |
Treatments |
NCT03105986 |
CR108300 | P1 |
Completed |
Healthy Volunteers |
2017-06-16 |
2019-03-21 |
Treatments |
|
NCT03010059 |
CR108251 | P1 |
Completed |
Healthy Volunteers |
2017-05-29 |
2019-03-21 |
||
NCT02833831 |
CR108169 | P1 |
Completed |
Healthy Volunteers |
2017-02-17 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT02813460 |
CR108168 | P1 |
Completed |
Healthy Volunteers |
2016-08-01 |
2019-03-20 |
Treatments |
|
NCT02478333 |
CR107180 | P1 |
Completed |
Respiratory Syncytial Virus Infections |
2015-07-01 |
2019-03-20 |
Treatments |
|
NCT02231671 |
ALS-008176-504 | P1 |
Completed |
Respiratory Syncytial Virus Infections |
2014-09-30 |
2019-03-20 |
Treatments |
|
JapicCTI-173788 |
JapicCTI-173788 | P2 |
Unknown |
Respiratory Syncytial Virus Infections |
2021-04-30 |
|||
NCT03332459 |
CR108375 | P2 |
Completed |
Respiratory Syncytial Virus Infections|Communicable Diseases|Respiratory Sounds |
2020-04-13 |
15% |
2020-05-14 |
Primary Completion Date |
JapicCTI-184013 |
JapicCTI-184013 | P2 |
Terminated |
Respiratory Syncytial Virus Infections|Pneumovirus Infections |
2019-09-30 |
|||
2017-001696-22 |
2017-001696-22 | P2 |
Temporarily not available |
Unknown |
2019-09-07 |
39% |
2022-03-13 |
Treatments |
JapicCTI-173762 |
JapicCTI-173762 | P2 |
Terminated |
Respiratory Syncytial Virus Infections |
2019-05-26 |
|||
NCT03502694 |
STEP | P2 |
Withdrawn |
Respiratory Syncytial Virus Infections|Pneumovirus Infections |
2019-04-30 |
39% |
2019-03-22 |
|
JapicCTI-163405 |
JapicCTI-163405 | P2 |
Terminated |
Respiratory Syncytial Virus Infections |
2018-12-31 |
|||
2017-001862-56 |
PLUM | P2 |
Terminated |
Respiratory Syncytial Virus Infections |
2018-10-16 |
64% |
2022-03-13 |
Treatments |
2016-001653-40 |
A Phase 2b study for adults with Respiratory Syncytial Virus. | P2 |
Terminated |
Respiratory Syncytial Virus Infections |
2018-10-16 |
59% |
2022-03-13 |
Treatments |
NCT02935673 |
CR108217 | P2 |
Terminated |
Respiratory Syncytial Virus Infections |
2018-07-17 |
59% |
2019-03-21 |
Treatments |
NCT03333317 |
CR108367 | P2 |
Terminated |
Respiratory Syncytial Virus Infections |
2018-03-23 |
64% |
2019-03-21 |
Treatments |
2016-001641-79 |
2016-001641-79 | P2 |
Terminated |
Respiratory Syncytial Virus Infections |
2017-03-30 |
2022-03-13 |
Treatments |
|
NCT02673476 |
ALS-8176-510 | P2 |
Completed |
Respiratory Syncytial Virus Infections |
2016-10-31 |
2019-03-20 |
Treatments |